HIV market will see modest growth to $22.5 billion by 2025, report
The human immunodeficiency virus (HIV) market across the nine major countries of the USA, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China, is set to grow from $16.3 billion in 2015 to $22.5 billion by 2025, representing a compound annual growth rate of just over 3%.
According to research and consulting firm GlobalData’s latest report, this relatively modest growth will mainly be driven by the introduction of novel drugs, an increasing number of people living with HIV who are treated with antiretroviral therapy (ART), and increased efforts to identify new infections through aggressive screening and diagnostic policies. The adoption of the test-and-treat approach to increase the number of patients on ART and reduce viral loads will also be a factor.
Unmet needs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze